KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors

Imatinib and other BCR-ABL1 inhibitors are effective therapies for chronic myeloid leukemia (CML), but these inhibitors target additional kinases including KIT, raising the question of whether off-target effects contribute to clinical efficacy. Based on its involvement in CML pathogenesis, we hypoth...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Corbin, Amie S., O’Hare, Thomas, Gu, Zhimin, Kraft, Ira L., Eiring, Anna M., Khorashad, Jamshid S., Pomicter, Anthony D., Zhang, Tian Y., Eide, Christopher A., Manley, Paul W., Cortes, Jorge E., Druker, Brian J., Deininger, Michael W.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2013
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3894913/
https://ncbi.nlm.nih.gov/pubmed/23887971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1318
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items